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Abstract 
Catestatin (CST), a fragment of Chromogranin-A, exerts angiogenic, arteriogenic, 
vasculogenic and cardioprotective effects.  CST is a very promising agent for 
revascularization purposes, in “NO-OPTION” patients. However, peptides have a very short 
half-life after administration and must be conveniently protected. Fibronectin-coated 30 
pharmacologically active microcarriers (FN-PAM), are biodegradable and biocompatible 
polymeric microspheres that can convey mesenchymal stem cell (MSCs) and therapeutic 
proteins delivered in a prolonged manner. In this study, we first evaluated whether a small 
peptide such as CST could be nanoprecipitated and incorporated within FN-PAMs. 
Subsequently, whether CST may be released in a prolonged manner by functionalized FN-35 
PAMs (FN-PAM-CST). Finally, we assessed the effect of CST released by FN-PAM-CST on 
the survival of MSCs under stress conditions of hypoxia-reoxygenation. An experimental 
design, modifying three key parameters (ionic strength, mixing and centrifugation time) of 
protein nanoprecipitation, was used to define the optimum condition for CST. An optimal 
nanoprecipitation yield of 76% was obtained allowing encapsulation of solid CST within FN-40 
PAM-CST, which released CST in a prolonged manner. In vitro, MSCs adhered to FN-
PAMs, and the controlled release of CST from FN-PAM-CST greatly limited hypoxic MSC-
death and enhanced MSC-survival in post-hypoxic environment. These results suggest that 
FN-PAM-CST are promising tools for cell-therapy. 
 45 
 
Key words: microcarriers, drug delivery, catestatin, mesenchymal stem cells, hypoxia 
 3 
1. Introduction 
Prolonged hypoxia an oxidative stress conditions are responsible of the damage observed in 50 
the cardiovascular system in several pathological situations; consequently prolonged effects 
of pro-survival factors are necessary tools to limit such a damage. Among emerging peptides 
in the cardiovascular system Chromogranin-A (CgA) derived peptides are occupying a role 
of paramount importance. CgA is a key player in the neuroendocrine regulation of cardiac 
function. In fact, CgA is ubiquitously distributed in the nervous system, immune system and 55 
diffuse neuroendocrine system of both vertebrates and invertebrates (Helle, 2004; Penna et al., 
2012; Pieroni et al., 2007). CgA is a pro-hormone which is stored in vesicles (Taupenot et al., 
2003) and its processing gives rise to several peptides of biological importance, including 
serpinin, pancreastatin, vasostatin, and Catestatin (CST) (Penna et al., 2012). 
CST is a 21-amino acid derivate of CgA and initially it was described as a potent inhibitor of 60 
catecholamine release from adrenal medulla (Ratti et al., 2000; Tota et al., 2003), but in the 
last years several new biological activities have been described, including a cardioprotective 
role. Moreover a myocardial production of CST was demonstrated recently (Bassino et al., 
2011; Bassino et al., 2015; Biswas et al., 2010; Penna et al., 2010; Penna et al., 2012; Perrelli 
et al., 2013). The anti-adrenergic effects of CST in the heart muscle seem to be mediated by 65 
the PI3K-Akt-eNO-Synthase signaling axis (Bassino et al., 2011; Bassino et al., 2015). 
Moreover a positive effect of CST on monocyte migration in-vitro and the induction of 
angiogenesis, arteriogenesis and vasculogenesis in the unilateral mouse hind limb ischemia 
model by a basic fibroblast growth factor (bFGF)-dependent mechanism has been 
demonstrated (Egger et al., 2008; Theurl et al., 2010). Based on the above-mentioned 70 
findings, it is clear that CST exerts a protective and proangiogenetic role via the activation of 
survival kinases.  
 
Hence, CST is a very promising agent for cardiovascular protective purposes; however, 
usually, proteins have a very short half-life after administration and must be conveniently 75 
protected. The combination of cardioprotective agents and the use of biomaterials to improve 
cell behavior within the infarcted area is an interesting approach in cardiovascular 
regenerative medicine. Pharmacologically active microcarriers (PAMs), biodegradable and 
biocompatible polymeric microspheres containing a bioactive protein, have the ideal 
characteristics for this purpose. Besides being able to deliver physiological doses of a 80 
relevant bioactive protein released in a controlled manner, they may also convey cells on 
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their 3-dimensional (3D) biomimetic surface of extracellular matrix molecules. In this way 
the combined action of the bioactive protein and the biomimetic surface can favor the 
survival and engraftment of the transported cells after their transplantation in different 
pathological conditions (Delcroix et al., 2011; Karam et al., 2012; Musilli et al., 2012; Quittet 85 
et al., 2015; Savi et al., 2015; Tatard et al., 2007). Recently, it has been shown that PAMs 
releasing vascular-endothelial-growth-factor (VEGF) and conveying MSCs (derived from the 
adipose tissue) may induce their proliferation, angiogenic differentiation, and a decrease in 
cell death in vitro (Penna et al., 2013; Madonna et al., 2015). Moreover, in an in vivo mice 
model of post-ischemic myocardium these functionalized PAMs implanted in the infarcted 90 
myocardium enhanced MSC engraftment and differentiation into vascular structures resulting 
in myocardial fractional shortening improvement (Madonna et al., 2015). Within this line, 
obtaining a prolonged release of physiological doses of bioactive CST, a small peptide that 
can diffuse within the tissue parenchyma and exert cardioprotective properties, is an 
interesting strategy. The delivered peptide may not only repair the damaged tissue, but also in 95 
combination with the 3D biomimetic surface of the PAMs act synergistically to enhance the 
engraftment of the transported MSCs. Fibronectin-covered PAMs that stimulate MSC 
survival (Garbayo el at 2011) and CST, a catecholamine release inhibitor with 
antihypertensive, proangiogenetic and cardioprotective properties (Penna et al., 2012), 
may be a novel ideal combination to repair the organ damage caused by an hypoxic insult. 100 
 
However, the prolonged and complete delivery of proteins at physiological doses still 
remains a technological challenge for effective clinical applications, mainly due to protein-
polymer interaction during the process and protein degradation related to acidic environment 
following degradation of PLGA (D,L-lactide-co-glycolide acid)  (Aubert-Pouessel et al., 105 
2002; Park et al., 1998). With the aim to enhance protection of the protein from degradation 
and to obtain a more efficient release, we developed a strategy based on the use of a 
reversible nano-precipitated protein associated to a triblock copolymer P188 (poly (ethylene 
oxide) (PEO)- poly(propylene oxide) (PPO)-poly(ethylene oxide)PEO) leading to protein 
protection, especially during the release step (Giteau et al., 2008). Protein precipitates were 110 
formed from aqueous solution at the pH corresponding to the isoeletric point (pI) of the 
protein by the addition of sodium chloride to a water-miscible organic solvent, Glycofurol 
(Karam et al., 2014;).  
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Our purpose in this study is to determine an appropriate method of nanoprecipitation of this 115 
small peptide, CST, for the encapsulation in PLGA-based microspheres preserving CST 
bioactivity. P188 will be used as a component of the microcarrier covalently linked to PLGA 
(PLGA-P188-PLGA) to render it more hydrophilic, thus avoiding denaturation by adsorption 
to hydrophobic surfaces, but also to retain the protective polymer inside the microcarriers 
during their degradation (Morille et al., 2013). We thereafter evaluated the release kinetics of 120 
CST and the ability of the bioactive CST released from functionalized PAMs to protect bone 
marrow MSCs in standard in vitro conditions.  
 
2. Materials and methods 
2.1 Chemicals and drugs 125 
Chemical reagents in general were purchased from Sigma Aldrich  (St. Louis, MO, USA) 
unless otherwise stated. Polyvinyl alcohol (Mowiol
®
 4-88) was obtained from Kuraray 
Specialities Europe (Frankfurt, Germany). P188 poloxamer or Lutrol® was kindly supplied 
by BASF (Levallois-Perret, France). PLGA–P188–PLGA were synthesized by IBMM-CRBA 
CNRS UMR 5247 (Montpellier, France) as previoulsy described (Morille et al., 2013). 130 
Polytetrafluoroethylene (PTFE) filters Millex®-FH (pore size 0.45 μm) were obtained from 
Millipore (Millipore SA, Guyancourt, France). Culture mediums, penicillin, streptomycin and 
trypsin were obtained from M-Medical (Milan, Italy). 
 
2.2 Protein precipitation and PAM formulation 135 
Protein, glycofurol, and sodium chloride were used without further purification. Experiments 
were carried out at 4° C and  the overall mixture was prepared directly inside a teflon tube. 
The protein powder was first dissolved in a non-buffered aqueous solution. In previous 
experiments (Karam et al., 2012, 2014), we showed that the best protein precipitation 
efficiency corresponds to the isoeletric point (pI) of the protein; for CST nanoprecipitation  140 
(pI CST 11.72). Then, we studied the possibility to adjust the pH of the solution by dissolving 
the salt into Glycine-NaOH buffer (pH 8.6). Sodium chloride was added at different 
concentrations, and at a later stage the poloxamer P188 was added in Glycine-Na-OH buffer 
to a 20:1 poloxamer-protein ratio; finally this solution was introduced into glycofurol. Thirty-
minutes later at +4°C, the protein particles were recovered by centrifugation (10,000g, 30 145 
min, +4°C). Mixing and centrifugation times were selected in order to optimize the quantity 
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of precipitated protein with an experimental design. 
 
After this, microspheres where made by a non-denaturing solid-in-oil-in-water (s/o/w) 
emulsion evaporation/extraction technique (Delcroix et al., 2011). Protein precipitates were 150 
dispersed in the organic phase (670 μL of 50 mg PLGA or PLGA–P188–PLGA dissolved in 
a 3:1 methylene chloride:acetone solution). The organic suspension was then emulsified in a 
poly (vinyl alcohol) aqueous solution (30 mL, 4% w/v at 1 °C) and mechanically stirred at 
550 rpm for 1 min. After addition of 33 mL of deionized water and stirring for 10 min, the 
emulsion was added to 167 mL deionized water and stirred for 20 min to extract the organic 155 
solvent. Finally, the microspheres were filtered on a 5 μm Small Volume Low Pressure 
(SVLP) type filter, washed and freeze-dried (Paillard-Giteau et al., 2010). PAM without 
protein were prepared following the same process, and called blank-microspheres (PAM) or 
FN-PAMs when covered with fibronectin (FN). To obtain FN-PAMs, PLGA-P188-PLGA 
microspheres were coated with FN and poly-D-Lysine (PDL). Coating solutions were 160 
prepared in Dulbecco's Phosphate-Buffered Saline DPBS.Each tube was covered with 
sigmacote® to prevent product loss on the tube walls. The concentration of the coating 
molecules was 9 μg/mL of FN and 6 μg/mL of PDL (corresponding to a 60:40 ratio of 
FN:PDL). 5 mg of PAM was added to DPBS and sonicated until full dispersion of the 
microspheres. The solution containing PDL and FN molecules was mixed to the 165 
microspheres suspension (final volume: 10 mL) and placed under rotation at 15 rpm at 37 °C 
during 1.5h. After coating, FN-PAMs were washed 3 times in distilled water, lyophilized and 
kept at − 20 °C. 
 
 170 
2.3 PAM characterization 
The surface morphology of the microspheres was investigated by scanning electron 
microscopy (SEM, JSM 6310F, JEOL, Paris, France). Freeze-dried microspheres were 
mounted onto metal stubs using double-sided adhesive tape, vacuum-coated with a film of 
carbon using a MED 020 (Bal-Tec, Balzers, Lichtenstein). The average particle size and size 175 
distribution were determined using a Coulter Multisizer (Beckman Coulter, Roissy, France). 
The microspheres were suspended in isotonic saline solution and sonicated for a few minutes 
prior to analysis. The mean particle sizes are expressed as volume distributions (N=3). 
 
Zeta potential measurement was performed using a Zetasizer 2000 (Malvern Instruments, 180 
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Orsay, France) operating at 150 V at RT was used to assess the variations of electrical surface 
charges of PAMs. Briefly, a suspension of PAMs at 0.3 mg/ml in 1 mM NaCl was measured 
after sonication (42 kHz, 10 s). Results are presented after conversion of electrophoretic 
mobility values to zeta-potential using Smoluchowski's equation. Experiments were 
performed in triplicate (N=3). 185 
 
The fibronectin surface was characterized by confocal microscopy after FN immunostaining. 
Lyophilized PAMs (1 mg) were suspended in DPBS containing 4% bovine serum albumin 
(BSA), 0.2% Tween 20 (DPBSBT) and incubated for 30 min at room temperature (RT) under 
15 rpm stirring. Samples were then washed three times with DPBS and centrifuged (9000 g, 5 190 
min, R.T.). Anti-FN mouse monoclonal antibody (1:100 in DPBSBT) was incubated at 37 °C 
for 1.5 h under rotation or overnight at +4°C. Samples were then washed 3 times before 
incubation with biotinylated anti-mouse IgG antibody (2.5 μg/mL in DPBS) for 1 h, at RT, 
under rotation. After three washes, samples were incubated with streptavidin–fluoroprobe 
547 H (1:500 in DPBS) at RT, for 40 min, under rotation. Samples were observed under 195 
confocal microscopy (Olympus Fluoview
TM
 FV2 300, Rungis, France). Three independent 
experiments were performed and every condition was observed in triplicate. 
 
2.4 Experimental design 
To define the optimum conditions of protein precipitation, an experimental design was used. 200 
We performed a preliminary experimental design (2
4-1 
fractional factorial design) with the 
aim to study the effect of 4 parameters and 3 interactions between these factors, supposing to 
influence the CST precipitation yield: the centrifugation speed, the contact time of mixture 
and the ionic strength of the protein aqueous solution (NaCl or ZnCl2 concentration). The 
studied interactions are: NaCl concentration- ZnCl2 concentration, NaCl concentration-205 
contact time, Time- ZnCl2 concentration. The effect of the tested experimental factors was 
calculated using NEMROD software (Mathieu and Nony, 2000). Subsequently, the 
parameters identified as influent on protein precipitation yield, were optimised with a 
Doehlert matrix. This experimental design represents an optimal design for the spherical 
domain defined by the two factors and it allows a sequential approach (Giteau et al., 2008)  . 210 
Experiments required for this design are described in Fig.1. It consists in a set of 7 distinct 
experiments uniformly distributed in a hexagonal plan (step 1). To approach the optimal 
conditions, three complementary experiments were added for the matrice expansion (step 2), 
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and two supplementary experiments were performed (step 3). The measured response was the 
precipitation efficiencies of CST (%). The same experiments were performed for each 215 
condition: this allowed a direct comparison of responses. 
 
2.5 Protein encapsulation efficiency  
Protein encapsulation yield was determined considering the CST total protein entrapped. 
Protein PLGA-P188-PLGA microspheres (5 mg) were dissolved in 500 l  220 
Dimethylformamide (DMF) in Teflon™ tube and vortexed. After 10 min 500 l of DMF was 
added and the solution was vortexed for 10 min more. The encapsulation efficiency was 
measured using NanoDrop 2000 Spectrophotometer (Thermo Scientific,France) immediately 
to avoid artifacts (N=3). 
 225 
2.6 Release Kinetics 
The release profile of protein from PLGA-P188-PLGA microspheres was determined by 
adding 500 l of PBS buffer, pH 7.4 to 5 mg of PAM-CST into eppendorf tubes. The tubes 
were closed and incubated in a shaking water bath (37°C, 125 r.p.m.). The tubes were 
centrifuged for 5-min. at 2800 g and 500 l of the supernatant were collected for analysis and 230 
replaced by fresh buffer. This procedure was repeated at different time-points (1, 2, 3, 4, 7, 
10, 14 and 21 days) and the released CST present in the collected aliquots was measured by 
NanoOrange
®
 protein quantification kit (Invitrogen, Cergy Pontoise, France) following the 
manufacturer’s guidelines. The theoretical amount of CST present in the 5 mg PAM-CST 
was corrected using the results of the encapsulation yield, thus allowing the actual amount of 235 
CST contained in the PAM-CST to be established. The cumulative release of CST- A over 
time was then calculated. Three independent experiments were performed. 
2.7 MSC isolation and cell culture  
Mesenchymal stem cells were extracted from bone marrow of femurs of Wistar rats 6–12 
months of age (weight 450–550 g; Janvier, Le Genest St Isle, France). MSCs were extracted 240 
by inserting a 21-gauge needle into the shaft of the bone and flushing with a solution of mini- 
mum essential medium eagle  (α-MEM) and 20% fetal bovine serum (FBS) (Sigma-
Aldrich, Milan, Italy) implemented with 2 mM glutamine, 100 U/ml penicillin and 100 
mg/ml streptomycin (Lonza); the cell suspension was filtered and cultured at 37°C. After 24-
hrs the medium was replaced with α -MEM containing 10% FBS, 2 mM glutamine, 100 U/ml 245 
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penicillin and 100 mg/ml streptomycin. We allowed MSCs to grow up to passage 3 (P3), 
replacing the medium every 2–3 days as reported in the literature (Gallo et al., 2007; Muscari 
et al., 2005; Penna et al., 2008; Raimondo et al., 2006; Wang et al., 2003). 
All animal experiments comply with the ARRIVE guidelines and are carried out in 
accordance with the U.K. Animals (Scientific Procedures) Act, 1986 and associated 250 
guidelines, EU Directive 2010/63/EU for animal experiments, as well as with the National 
Institutes of Health guide for the care and use of Laboratory animals (NIH Publications No. 
8023, revised 1978). The animal protocols followed in this study were approved by the local 
“Animal Use and Care” committees (RR # 145674720268, dated 08/04/2013). 
 255 
2.8 In vitro study: survival after hypoxia/reoxygenation  with and without pre-
treatment with free-CST, FN-PAMs or FN-PAM-CST 
Experiments were carried out with MSCs  alone or after pre-treatment of MSCs with either 
FN-PAMs, FN-PAM-CST or CST alone (free CST) in normoxic and hypoxic experimental 
condition, as previously described (Penna et al., 2013). Briefly, the bone marrow-MSCs were 260 
pre-treated with free CST (5 nM), FN-PAMs (0.5 mg) or FN-PAM-CST (0.5 mg) for 24-hrs. 
Before exposure to hypoxic condition, MSCs were incubated with trypsin-EDTA 0.25% 
solution and subjected to mild centrifugations (250–300 g for 5-min.) in order to separate 
cells from FN-PAMs or FN-PAM-CST. Then the medium was changed and cells were 
cultured in 2% FBS without treatment factors. Thereafter, subgroups of cells were subjected 265 
to a protocol of hypoxia/reoxygenation (H/R) (72/3 hrs) in a hypoxic chamber (INVIVO2 
200, Belsar, Varese, Italy). Accordingly the groups considered in the study of cell survival 
were the following (Fig.2):  
1) Untreated MSCs kept under standard conditions for 3-days (MSC- 3-N), and untreated 
MSCs exposed to H/R (MSC-3-H); 270 
2) MSCs pre-treated with FN-PAM and kept under standard conditions (FN-PAM-3-N), and 
MSCs pre-treated with FN-PAMs and exposed to H/R (FN-PAM-3-H);  
3) MSCs pre-treated with FN-PAM-CST and kept under standard conditions (FN-PAM-CST-
3-N), and MSCs pre-treated with FN-PAM-CST and exposed to H/R (FN-PAM-CST-3-H); 
 275 
4) MSCs pre-treated with free CST and kept under standard conditions (CST-3-N), and 
MSCs pre-treated with free CST and exposed to H/R (CST-3-H).  
 10 
 
In other words and in brief, in each of the above four groups, we considered normoxic (-N) 
and hypoxic (-H) protocols for comparative purpose.  280 
At the end of experiments, in triplicate in a blinded fashion, cell survival was assessed, using 
the cell viability test 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
assay (Sigma-Aldrich, Italy) (Wang et al., 2003).  
 
2.9 Statistical analysis  285 
Data are presented as mean +/- SEM. Statistical significance was performed with t test or 
one-way ANOVA (post-hoc test Newman-Keuls Multiple Comparison Test) using GraphPad 
Prisma. The results were considered significant when P< 0.05. 
 
3. Results  290 
3.1 Characterization of PAM  
Morphological features of PAM and release profile of CST from PAM are reported in Fig 3-I 
and 3-II, respectively. The average diameter and size distribution of the resulting 
microspheres were evaluated using a Multisizer® Coulter Counter. We obtained 
microspheres with a diameter of 60 μm ± 22 (Fig. 3-Ia). The morphological aspect of MS, 295 
determined by scanning electron microscopy (SEM), showed a spherical shape (Fig. 3-Ib,c). 
To obtain FN-PAMs, PLGA-P188-PLGA microspheres were coated with FN and Poly-D-
Lysine (PDL) (FN:PDL is 60:40). The microspheres had a zeta potential of 42,9±1,75 
indicating the coating of PDL on their surface allowing cell attachment. The fibronectin 
surface characterized by confocal microscopy after FN immunostaining (Fig. 3-Id,e) showed 300 
that they were covered by this extracellular matrix protein. 
 
3.2 Experimental design 
N°Exp NaCl Contact 
time 
Centrifugation 
speed 
ZnCl2 Nanoprecipitation 
yield 
(nemrod) M Min G M % 
1 0 30 10 000 0 16.2 
2 1 30 10 000 0.008 24.3 
3 0 60 10 000 0.008 32.3 
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4 
1 60 10 000 0 61.3 
1 60 10 000 0 63.4 
5 0 30 16 000 0.008 15.5 
6 1 30 16 000 0 27,4 
7 0 60 16 000 0 32.5 
8 
1 60 16 000 0.008 34.0 
1 60 16 000 0.008 40.3 
 
Table 1:  Fractional factorial design and nanoprecipitation yields for each experiment. 305 
The effects of the parameters studied and of the interactions between these parameters are 
shown in Table 1 and graphically represented in Fig. 4. Preliminary experiments, testing 
multiple parameters supposed influencing CST precipitation, reveal how centrifugation speed 
and use of ZnCl2 have a negligible effect on nanoprecipitation yield of CST (Fig.4). As 
shown in Table 1, we obtain low percentage of nanoprecipitation yield using ZnCl2 0.008M 310 
in combination with different centrifugation speeds. However, the difference in the ionic 
strength of the protein aqueous solution, using NaCl instead of ZnCl2, and the increased 
contact time of mixture have a positive effect (Fig.4) and lead to a higher nanoprecipitation 
yield (63.4%), as shown in Table 1. Subsequently, these two parameters identified as influent 
on protein precipitation yield, were optimised with a Doehlert matrix (Fig.5). We found that 315 
the optimal conditions to obtain a good percentage of CST nanoprecipitation of 76% of the 
initial protein (Step 3), was obtained by increasing the contact time of the mixture until 90 
min. at a 2.175 M NaCl.  Furthermore, in order to obtain a good precipitation yield the 
protein needs to be in a pH which is similar to its isoeletric point (Karam et al., 2014), so we 
dissolved the salt in Glycine-NaOH buffer (pH 8.6). This condition allowed to obtain the best 320 
protein precipitation efficiency. 
 
3.3 Release of CST from FN-PAM-CST 
The encapsulation yield of total protein into FN-PAM-CST was 62%. After the release 
kinetics study we found a continuous release of CST from these PAMs. The release profile 325 
showed a burst effect during the first 24 h of  almost 50% of CST corresponding to 15 µg for 
5mg of PAM (Fig.3-II). This initial burst is followed by a quite homogeneous and continuous 
release until the end of the release period. The total amount released in three weeks for 5 mg 
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PAMs corresponded to around 45 µg, which is within the range of the physiological doses of 
CST that may be used with around 1 mg PAMs in vitro. The release profile observed at the 330 
end of 3 weeks shows a cumulative release representing 100% of the entrapped protein.  
 
3.4 Survival after H/R with and without pre-treatment with free CST, FN-PAMs or FN-
PAM-CST 
Data of survival analysis after H/R in pre-treated cells are presented as percent variation with 335 
respect to mean value of the cell count in control condition (MSC-3-N). To choose the 
optimal dose of CST, we performed experiments testing at least three different concentrations 
of free CST (5 nM, 10 nM and 2.5 μM). While the higher concentration resulted toxic 
(induced cell death), the two lower concentrations similarly increased cell survival (data no 
shown), thus we decided to continue to test the lower concentration and to use 0.5 mg 340 
PAMs/15x10
4
 cells in order to obtain a similar concentration of CST in dishes in the 
following experiments. This proportion corresponds to what has been used in different 
experiments (Penna et al., 2010; Bassino et al., 2015). 
 
As can be seen in Fig 6a, in the absence of pre-treatment (CTRL), the H/R protocol induced a 345 
20% reduction in MSC number (p< 0.01 vs control). While this H/R protocol was unable to 
induce cell death in the presence of FN-PAM, in the presence of either free CST or FN-PAM-
CST, the MSC continued to even proliferate despite the H/R protocol (p< 0.01 vs H/R only, 
for both).  Therefore, pre-treatment with either CST and/or FN-PAM are able to counteract 
hypoxia effects. 350 
We also analyzed MSC proliferative behavior in normoxia (Fig 6b)  and found out that CST 
was able to induce a slight proliferation, which was ameliorated by FN-PAM-CST. In fact, in 
normoxia MSC proliferation increased significantly with FN-PAM-CST only.  
These results suggest that there is no loss of bio-activity of CST after nanopreciptation 
procedure, which actually slightly improved the activity of free CST, when slowly released 355 
from FN-PAM.  Moreover, in H/R experiments, pre-treatment with FN-PAM-CST not only 
limited cell mortality, but also improved cell growth.  
 
4. Discussion 
Catestatin is a promising agent for cardiovascular protective purposes and use of PAMs to 360 
convey MSCs, and/or to deliver CST could be a good approach to repair the damage 
observed in the cardiovascular system in several pathological situations. In this study, we 
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have hypothesized that a continuous release of physiological low doses of CST by FN-PAM 
may act on cells and counteract in a better way prolonged oxidative- and hypoxic-induced 
stress. Within this context, the major new findings of this study are: 1) CST can be nano-365 
precipitated in order to preserve its structure for encapsulation studies; 2) Nanoprecipitated 
CST can be encapsulated in FN-PAMs; 3) functionalized FN-PAMs can slowly release a 
bioactive CST; 4) FN-PAMs induce MSC proliferation in normoxia potentiated by the 
functionalization with CST and 5) FN-PAM-CST protect bone marrow MSC from 
hypoxia/reoxygenation stress. 370 
 
The encapsulation and the sustained release of a protein from microspheres is a difficult task 
and depends on the physicochemical characteristics of each protein such as molecular weight, 
hydrophilicity and stability (Bilati et al., 2005). In particular, the low molecular weight of 
CST represented a challenge for the prolonged release of this small peptide in an active state 375 
from the microspheres. We have previously shown that proteins encapsulated under a 
nanosolid state within a PLGA polymer preserve their structure and integrity, allowing a 
better and prolonged release profile and the maintenance of their biological activity (Penna et 
al., 2013). In order to optimize the preparation of small peptides, various methods like spray-
drying or spray-freeze drying have been reported (Lam et al., 2000; Wang et al., 2004). Even 380 
if these methods can generate protein particles, they have several disadvantages, such as the 
complexity of the technique, leading to low protein recovery and, above all, they may 
denature proteins. From an aqueous solution, protein precipitation can be induced for 
example with the addition of polymers or salts, with the reduction of the protein charge by 
changing the pH, or with the reduction of the dielectric constant by the addition of water-385 
miscible organic solvents (Cleland and Jones, 1996) increasing ionic strength. The salt-
induced precipitation is an extensively used method in biotechnology for separating target 
proteins from multi-components protein solutions as the first purification (Arakawa et al., 
1991; Foster et al., 1971; Rothstein, 1994). In our experimental setup, a high amount of salt is 
necessary for CST nanoprecipitation and encapsulation, while preserving its bioactivity. 390 
 
With the aim to determine an appropriate method of precipitation of CST for the 
encapsulation in PLGA-P188-PLGA microspheres preserving CST bioactivity we performed 
an experimental design testing different parameters. Indeed the ionic strength can be used to 
stimulate the salt induced precipitation: sodium chloride reduces the electrostatic repulsive 395 
interaction between the charged proteins, promoting in this way attractive hydrophobic 
 14 
interaction (Tobler et al., 2000; Vonhippel and Wong, 1964). However the increase of ionic 
strength was limited by the solubility of the salt used (NaCl 2.175 M) and by the formation of 
artefacts during the mixing. Moreover, excess salt-induced precipitation may induce proteins 
to incorrectly fold or to form insoluble aggregates upon re-dissolution (Tobler et al., 2000). 400 
We have furthermore employed an organic solvent to induce the formation of fine protein 
particles. Nanosized protein particles were formed by the addition of excess glycofurol, an 
organic solvent miscible in water, to the aqueous solution (Giteau et al., 2008). Glycofurol 
has been previously used to induce the formation of nanosized solid protein particles (Giteau 
et al., 2008; Karam et al., 2014), but to our knowledge, this is the first time that such a small 405 
peptide (21-amino acids) is efficiently precipitated with this method. Another parameter 
tested in the experimental design was the time of incubation of the mix of CST with sodium 
chloride and organic solvents. We observed an increased percentage of nanoprecipitation 
yield correlated to the increase in time of incubation.  We obtained in fact a very good CST 
precipitation at 90 minutes of incubation.  410 
 
Furthermore, P188 poloxamer was added to the mix to co-precipitate with the protein. This 
non-ionic surfactant,  comprised of hydrophobic and hydrophilic segments will surround 
and protect the protein by limiting its adsorption onto the hydrophobic surface of the PLGA 
polymer (Morille et al., 2013; Mustafi et al., 2008). It was co-precipitated with CST at the 415 
ratio of 1:20 of protein:additive polymer, and allowed a  complete release of CST. This 
formulation  allows a complete  CST release from the PAMs, probably due to a better 
diffusion of the protein and an enhanced protection within the core. In this study CST 
precipitation with glycofurol, sodium chloride and P188 in optimum conditions allowed 
obtaining stabilization during the encapsulation process without loss of bioactivity. In 420 
particular, the hydrophilic P188, limiting the protein interaction with the PLGA 
hydrophobic polymer surface, protects the protein, increases their biological activity 
and may favor protein release into the media. Actually, PAMs containing higher 
proportions of free P188 with the same protein content enhance active protein release 
(Morille et al., 2013). Therefore, P188 may certainly influence active protein release 425 
from triblock PLGA-P188-PLGA PAMs. In fact, 50% of CST was released during the first 
24h in vitro. Such an abundant release in the initial phase of a post-ischemic therapeutic 
approach may be a positive feature. Indeed the first phase of reperfusion is the more 
critical for tissue salvage (Penna et al., 2012). The later phases may be critical for tissue 
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repair and regeneration and a continuous slow release of a therapeutic peptide (e.g. 430 
VEGF and CST) released by microspheres transporting cells on their 3D functionalized 
surface may be beneficial for tissue engineering strategies (Elçin et al., 2001; Madonna 
et al., 2015). However, this needs to be ascertained in vivo for CST, and it should be 
ascertained whether other conditions, such as fibronectin coating, may affect the 
release of the active peptide. 435 
 
As demonstrated by us and other authors, CST is a very promising agent for a cardiovascular 
protective purpose (Bassino et al., 2011; Bassino et al., 2015; Egger et al., 2008; Penna et al., 
2010; Perrelli et al., 2013). In order to reduce damage observed in cardiovascular system 
following oxidative stress and prolonged hypoxic conditions, therapies with cell 440 
transplantation could represent a good strategy to follow; however approaches adapted to the 
varying conditions are needed. We have recently shown that VEGF-A as such or slowly 
released by FN-PAM can differently affect survival kinases and anti-apoptotic mediators, in 
stem cells (Penna et al., 2013). 
 445 
On the basis of the above reported data, we have  hypothesized that the prolonged release of 
CST by FN-PAM may act on cells and counteract in a better way prolonged hypoxic-induced 
stress. The in vitro study with CST-PAM suggested that it is possible to yield a good and 
effective complex to be used against hypoxia/reoxygenation damage. PAMs represents a 
multifunction vehicle that can be used in many contexts and with a variety of cells and 450 
proteins , and could be considered a new approach to improve MSC survival in the 
pathological hostile environment. 
 
A way to improve the efficiency of cell graft, for instance, is to design a scaffold able to 
deliver a bioactive therapeutic protein that is released in a controlled manner but also a 455 
scaffold that provides a biomimetic surface. PAMs represent an efficient and adaptable 
device for tissue engineering; they are biodegradable and non-cytotoxic microcarriers that 
provide an adequate 3D support for cell culture and/or for their administration (Delcroix et al., 
2010). Depending on the choice of the encapsulated protein and also of the molecule used for 
the biomimetic coating, PAM represents a multifunction vehicle that can be used in many 460 
contexts and with a variety of cells.  
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5.  Conclusions 
Our data are in line with the viewpoint that the use of FN-PAMs complexed with therapeutic 
proteins could be considered a new approach to improve cell survival in hostile environments 465 
such as inflammatory and post-ischemic tissue. Within this context, it has been previously 
shown that the 3D biomimetic support provided by FN-PAMs on their own, without 
delivering a therapeutic factor, already increases the survival of MSCs transported by these 
PAMs and implanted in the brain after global ischemia (Garbayo et al., 2011). Moreover, 
they enhanced the neuroprotective effect of the implanted MSCs.  470 
In this in vitro study, we have shown that CST can be encapsulated into PAMs and that this 
functionalized PAMs can protect bone marrow MSC from hypoxia/reoxygenation injury. If 
confirmed in an appropriate pre-clinical model, this approach may be envisaged for future 
clinical studies on tissue regeneration. 
 475 
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FIGURE CAPTATIONS 
Fig.1: Spatial representation of experiments varying in the defined experimental 
domain for CST nanoprecipitation. The table represents the values of each studied factor 485 
(NaCl and Time) for the different experiments. 
 
Fig.2: Protocols and time-lines for experimental groups in hypoxia/reoxygenation. 
Timing of various  interventions  is shown  in  relation to  the onset  of cell culture. 
Mesenchymal stem cells (MSCs) were kept at 21% O2  conditions  for  1 day during the pre-490 
treatments,  subsequently they  were  subjected   to  3 days hypoxia and 3 hrs reoxygenation. 
Fibronectin-coated pharmacologically-active-microcarriers (FN-PAM), FN-PAM 
incorporating  CST (FN-PAM- CST) or free CST were added at time 0. For comparative 
purpose we considered normoxic  (-N) and hypoxic (-H) protocols.  
 495 
Fig.3: Panel I, PAM characterization. PAM size distribution had an average diameter of 60 
μm (a). SEM images show a smooth surface and confirm the size distribution (b,c). The 
surrounding biomimetic coating was distributed homogenously at their surface as shown by 
the confocal image of fibronectin immunofluorescence (c, d). Panel II, Cumulative release 
of CST from microspheres up to 21 days. Each point represents the mean of triplicate 500 
experiments. 
 
Fig.4: Parameters and interaction studied. Graphical representation of the effects of the 
parameters and interaction studied  (Nemrod Software). 
 505 
Fig.5: Graphical representation of the measured responses as precipitation efficiencies. 
In the 3D view of the experimental domain, the directions of variation of the factor values are 
represented by arrows and the results by dots. 
*mean  of three values :  
(a) : 57±2%  510 
(b) : 45 ±3.5% 
(c) : 43±2% 
(d) : 76±3.5% 
 
Fig. 6: Panel a), Survival analysis. Cell growth in normoxia for 3-days (blue bar), and cell 515 
survival after 3-days hypoxia and 3-hrs reoxigenation (H/R)  of MSC pretreatred or not with 
factors (free CST, FN-PAMs or FN-PAM-CST).  Data are % variation with respect to mean 
value of MSCs kept under standard conditions for 3-days (MSC-3-N). Pre-treatment with 
FN-PAM-CST is able to counteract hypoxia-induceed cell number reduction. 
Panel b), Proliferative analysis. Cell growth in normoxia for 3-days of MSC pretreatred or 520 
not with factors (free CST, FN-PAMs or FN-PAM-CST).  Data are % variation with respect 
to mean value of MSCs kept under standard conditions for 3-days (MSC-3-N).    
* P< 0,01 vs CTRL normoxia    # P< 0,01 vs CTRL H/R 
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